CBER Director Zoon Leaving FDA, Will Assume Position At NCI In January
This article was originally published in The Gray Sheet
Executive Summary
Center for Biologics Evaluation & Research Director Kathryn Zoon's January departure coincides with the establishment of the FDA office of combination products under MDUFMA